<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity default-currency="CAD" hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-301-2-108403-001</iati-identifier>
  <reporting-org ref="XM-DAC-301-2" type="15">
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   <narrative xml:lang="EN">International Development Research Centre</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">SLAMF6 and 2B4: Roles and modes of action in normal immunity and cancer immunotherapy</narrative>
   <narrative xml:lang="FR">SLAMF6 et 2B4 : r&#xF4;les et modes d&#x2019;action dans l&#x2019;immunit&#xE9; normale et l&#x2019;immunoth&#xE9;rapie anticanc&#xE9;reuse</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">A functioning immune system is critical for successful treatment of cancer. Recent studies have shown an improvement of the immune response against cancer triggered by new drugs that block the function of certain types of receptors at the surface of immune cells. This project seeks to understand the role of two new potential molecular targets for immunotherapy against cancer in humans: the SLAMF6 receptor and the 2B4 receptor. 

These receptors are at the surface of key immune cells (CD8+T and NK lymphocytes), and they play an important regulatory role during the anti-tumor response mediated by these cells. The research team hypothesizes that pharmacological targeting of SLAMF6 and 2B4 could be helpful in the treatment of cancer. Findings from this research project will further basic knowledge of the role of SLAMF6 and 2B4 in immune cells, and determine whether these two receptors are valid clinical targets for pharmacologic treatment of human cancers.  

The project is led in Canada by the Institut de recherches cliniques de Montr&#xE9;al (affiliated with the University of Montreal), in collaboration with the Hadassah Hebrew University (Israel), Universidad Aut&#xF3;noma del Estado de Morelos (Mexico), and the Hebrew University (Israel). 

This project was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, which is a partnership between Canada&#x2019;s International Development Research Centre, the Canadian Institutes for Health Research, the Israel Science Foundation and the Azrieli Foundation. This 7-year, $35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. Projects include a plan for integrating researchers from low- and middle-income countries that will establish long-term scientific relationships.</narrative>
   <narrative xml:lang="FR">Un syst&#xE8;me immunitaire fonctionnel est essentiel pour un traitement efficace contre le cancer. Des &#xE9;tudes r&#xE9;centes ont d&#xE9;montr&#xE9; que de nouveaux m&#xE9;dicaments qui bloquent la fonction de certains types de r&#xE9;cepteurs &#xE0; la surface des cellules immunitaires entra&#xEE;nent une am&#xE9;lioration de la r&#xE9;action immunitaire contre le cancer. Ce projet vise &#xE0; comprendre le r&#xF4;le de deux nouvelles cibles mol&#xE9;culaires potentielles pour l&#x2019;immunoth&#xE9;rapie contre le cancer chez l&#x2019;humain : le r&#xE9;cepteur SLAMF6 et le r&#xE9;cepteur 2B4. 

Ces r&#xE9;cepteurs sont pr&#xE9;sents &#xE0; la surface des principales cellules immunitaires (lymphocytes T CD8+ et lymphocytes NK) et jouent un r&#xF4;le r&#xE9;gulateur important pendant la r&#xE9;action antitumorale induite par ces cellules. L&#x2019;&#xE9;quipe de recherche &#xE9;met l&#x2019;hypoth&#xE8;se que le ciblage pharmacologique des r&#xE9;cepteurs SLAMF6 et 2B4 pourrait &#xEA;tre utile pour traiter le cancer. Les r&#xE9;sultats de ce projet de recherche am&#xE9;lioreront les connaissances de base sur le r&#xF4;le des r&#xE9;cepteurs SLAMF6 et 2B4 dans les cellules immunitaires et permettront de d&#xE9;terminer si ces deux r&#xE9;cepteurs constituent des cibles cliniques valides pour le traitement pharmacologique des cancers humains. 

Le projet est dirig&#xE9; au Canada par l&#x2019;Institut de recherches cliniques de Montr&#xE9;al (affili&#xE9; avec l&#x2019;Universit&#xE9; de Montr&#xE9;al), en collaboration avec l&#x2019;Universit&#xE9; h&#xE9;bra&#xEF;que Hadassah (Isra&#xEB;l), l&#x2019;Universidad Aut&#xF3;noma del Estado de Morelos (Mexique) et l&#x2019;Universit&#xE9; h&#xE9;bra&#xEF;que (Isra&#xEB;l). 

Ce projet et son financement ont &#xE9;t&#xE9; approuv&#xE9;s par le deuxi&#xE8;me concours de recherche du Programme conjoint canado-isra&#xE9;lien de recherche en sant&#xE9;, un partenariat entre le Centre de recherches pour le d&#xE9;veloppement international du Canada, les Instituts de recherche en sant&#xE9; du Canada, l&#x2019;Israel Science Foundation et la Fondation Azrieli. Ce programme canado-isra&#xE9;lien de sept ann&#xE9;es, qui dispose d&#x2019;un budget de 35 millions CAD, met &#xE0; contribution les comp&#xE9;tences scientifiques uniques des deux pays et facilite le r&#xE9;seautage avec les pairs en Afrique, en Asie et en Am&#xE9;rique latine. Les projets incluent un plan d&#x2019;int&#xE9;gration de chercheurs de pays &#xE0; faible revenu et &#xE0; revenu interm&#xE9;diaire qui permettra d&#x2019;&#xE9;tablir des relations scientifiques &#xE0; long terme.</narrative>
  </description>
  <participating-org role="1" type="24">
   <narrative xml:lang="EN">Azrieli Foundation</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="FR">Canada. Parlement</narrative>
   <narrative xml:lang="EN">Canada. Parliament</narrative>
  </participating-org>
  <participating-org role="2" type="24">
   <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
  </participating-org>
  <participating-org role="4" type="24">
   <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
  </participating-org>
  <participating-org role="3" type="15">
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   <narrative xml:lang="EN">International Development Research Centre</narrative>
  </participating-org>
  <activity-status code="3"></activity-status>
  <activity-date iso-date="2016-11-01" type="2"></activity-date>
  <activity-date iso-date="2020-02-03" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
   </organisation>
   <telephone>(+1) 613-236-6163</telephone>
   <email>info@idrc.ca</email>
   <website>http://www.idrc.ca</website>
   <mailing-address>
    <narrative xml:lang="FR">CP 8500, Ottawa ON Canada, K1G 3H9</narrative>
    <narrative xml:lang="EN">PO Box 8500, Ottawa ON Canada, K1G 3H9</narrative>
   </mailing-address>
  </contact-info>
  <activity-scope code="1"></activity-scope>
  <recipient-region code="998" percentage="100" vocabulary="1"></recipient-region>
  <sector code="1" percentage="100" vocabulary="99">
   <narrative xml:lang="FR">Autre</narrative>
   <narrative xml:lang="EN">Other</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1"></sector>
  <policy-marker code="1" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="5" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1"></policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-11-17"></transaction-date>
   <value currency="CAD" value-date="2016-11-17">166666</value>
   <provider-org>
    <narrative xml:lang="EN">Azrieli Foundation</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-11-17"></transaction-date>
   <value currency="CAD" value-date="2016-11-17">166666</value>
   <provider-org>
    <narrative xml:lang="EN">Azrieli Foundation</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-11-17"></transaction-date>
   <value currency="CAD" value-date="2016-11-17">469892</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-11-17"></transaction-date>
   <value currency="CAD" value-date="2016-11-17">469892</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2016-11-18"></transaction-date>
   <value currency="CAD" value-date="2016-11-18">27777</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2016-11-18"></transaction-date>
   <value currency="CAD" value-date="2016-11-18">78315</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2017-05-01"></transaction-date>
   <value currency="CAD" value-date="2017-05-01">27777</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2017-05-01"></transaction-date>
   <value currency="CAD" value-date="2017-05-01">78315</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2017-11-01"></transaction-date>
   <value currency="CAD" value-date="2017-11-01">27777</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2017-11-01"></transaction-date>
   <value currency="CAD" value-date="2017-11-01">78315</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2018-05-31"></transaction-date>
   <value currency="CAD" value-date="2018-05-31">27777</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2018-05-31"></transaction-date>
   <value currency="CAD" value-date="2018-05-31">78315</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2018-11-01"></transaction-date>
   <value currency="CAD" value-date="2018-11-01">27777</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2018-11-01"></transaction-date>
   <value currency="CAD" value-date="2018-11-01">78315</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-05-01"></transaction-date>
   <value currency="CAD" value-date="2019-05-01">19444</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-05-01"></transaction-date>
   <value currency="CAD" value-date="2019-05-01">54820</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-12-04"></transaction-date>
   <value currency="CAD" value-date="2019-12-04">23494</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-12-04"></transaction-date>
   <value currency="CAD" value-date="2019-12-04">8333</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">-166666</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">-469891</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">166666</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">469891</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <conditions attached="1">
   <condition type="2">
    <narrative xml:lang="EN">Grant is conditional on completion of specified terms of reference, receipt of specified deliverables</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de respecter le mandat &#xE9;tabli et de livrer les r&#xE9;sultats attendus</narrative>
   </condition>
   <condition type="3">
    <narrative xml:lang="EN">Grant is conditional on periodic submission of a detailed accounting of expenditure of funds received from IDRC accompanied by estimation of budget for the next reporting period</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de p&#xE9;riodiquement pr&#xE9;senter une justification d&#xE9;taill&#xE9;e de l&apos;utilisation des fonds vers&#xE9;s par le CRDI ainsi qu&apos;une estimation budg&#xE9;taire de la p&#xE9;riode de rapport suivante</narrative>
   </condition>
  </conditions>
 </iati-activity>
</iati-activities>
